Komipharm Receives IND Approval for PAX-1 Phase 2 Clinical Trial Targeting Glioblastoma

[Asia Economy Reporter Minji Lee] Comipharm announced on the 4th that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a Phase 2 clinical trial plan to evaluate the safety and efficacy of PAX-1 in patients newly diagnosed with glioblastoma and recurrent glioblastoma.